Biotech: Page 3
-
Stock via Getty Images
Q&AAutobahn’s road to a breakthrough depression treatment is paved with high-profile investors
The biotech boasts some Big Pharma backers that drove a $100 million fundraising effort in July to take its depression drug into a mid-stage study.
By Amy Baxter • Aug. 7, 2024 -
Permission granted by Arialys Therapeutics
Biotech SpotlightA biotech dousing ‘fires’ in the brain that plagued a bestselling author
Arialys Therapeutics is developing a precision medicine treatment for a rare autoimmune encephalitis that mimics psychosis.
By Alexandra Pecci • Aug. 7, 2024 -
Explore the Trendline➔
Stock via Getty Images
TrendlineCommercialization, marketing and social media
As the pharma industry stares down a historic patent cliff, macroeconomic headwinds and challenging R&D costs for increasingly complex medicines, nailing the launch of new medicines has become increasingly critical.
By PharmaVoice staff -
Permission granted by Moderna
Pfizer, GSK and Moderna execs remain optimistic about RSV vaccines despite CDC blowback
An advisory committee’s age group recommendations look like a major setback, but executives are painting a rosier picture.
By Michael Gibney • Aug. 6, 2024 -
Permission granted by University of Pennsylvania
Jim Wilson, prominent gene therapy researcher, to depart UPenn
Wilson, who founded UPenn’s gene therapy program three decades ago, will step down to start two new spinouts, Gemma Bio and Franklin Biolabs.
By Ned Pagliarulo • Aug. 5, 2024 -
Stock via Getty Images
In a Duchenne market beset by problems, Capricor data marks a bright spot
The company’s cell therapy recently showed positive results from a mid-stage trial.
By Kelly Bilodeau • Aug. 5, 2024 -
Stock via Getty Images
OpinionWhat pharma has learned from AI
As AI tools move from hype to a daily reality at pharma companies, here are the insights users are gaining.
By Meagan Parrish • Aug. 2, 2024 -
Stock via Getty Images
Read to lead: 6 books pharma execs swear by
From an epic, alternative reality fantasy to a ‘biography of cancer,’ these six reads have stuck with pharma execs as they navigate how to lead.
By Alexandra Pecci • Aug. 1, 2024 -
Stock via Getty Images
Neuro drugs are still faltering, despite rising investment
A brain-on-a-chip developer says better preclinical modeling could help move the needle.
By Kelly Bilodeau • July 29, 2024 -
Permission granted by Biogen
Sage’s recent trial failure adds pressure to its two-drug Biogen collab
The mid-stage failure leaves the success of the expensive partnership hanging on a drug that’s already suffered its own setback.
By Amy Baxter • July 29, 2024 -
Stock via Getty Images
Citius’ first FDA decision date is approaching — and its CEO has millions on the line
Citius Pharmaceuticals CEO Leonard Mazur has personally invested $22.5 million into the company, which is fast approaching a potential turning point.
By Amy Baxter • July 26, 2024 -
Permission granted by Mubadala Capital
Q&AIn biotech’s new market normal, here’s what’s catching this investor’s eye
A VC investor shares how the market is recovering, which kinds of companies he’s hunting for and where he’d love to see more innovation.
By Meagan Parrish • July 25, 2024 -
Brian Tucker / BioPharma Dive
Private biotech M&A surges amid difficult IPO market
Private biotech company acquisitions are on their fastest pace in years, a trend some in the industry say is driven by the abundance of mature, but not yet public, drug startups.
By Gwendolyn Wu • July 23, 2024 -
Alex Wong / Staff via Getty Images
Q&ABird flu puts BARDA back in the spotlight
BARDA director Gary Disbrow explains the agency’s focus, how companies can get their “foot in the door” and why platforms are so important for preparedness.
By Alexandra Pecci • July 23, 2024 -
Stock via Getty Images
Kyverna follows oncology’s CAR-T cell playbook for an ultra-rare autoimmune disorder
The pharma company is tackling the “stiff person syndrome” that afflicts Celine Dion in a phase 2 trial for its lead CAR-T candidate.
By Amy Baxter • July 19, 2024 -
Permission granted by Amylyx
Q&AAmylyx’s CEOs on their ALS setback and quest to revamp the pipeline
Co-CEOs Josh Cohen and Justin Klee reflect on what they learned from Relyvrio’s failure and how they’re carrying those lessons forward with other drugs.
By Meagan Parrish • July 17, 2024 -
Doucefleur via Getty Images
Biotech SpotlightA new biotech tackling IBD joins a race against Lilly and Gilead for a promising pill
Ensho Therapeutics just launched but is already generating buzz with its phase 2-ready clinical program for inflammatory bowel disease.
By Alexandra Pecci • July 17, 2024 -
Getty Images via Getty Images
Has pharma emerged from the ‘age of uncertainty’?
An industry reeling from a precarious market is showing signs of stabilizing as the future becomes a little less cloudy, an Evaluate report suggests.
By Michael Gibney • July 16, 2024 -
Stock via Getty Images
Is a better CAR-T cell therapy option on the horizon?
In vivo CAR-T cell technology has the potential to solve some major issues in the field and could enter the clinic this year.
By Kelly Bilodeau • July 15, 2024 -
Stock via Getty Images
Biotech SpotlightMining clues from a library of brain tissue samples, Cerevance takes a precision approach to CNS disorders
Mid-stage data from the company’s lead candidate in Parkinson’s is expected later this year and could tee up an IPO.
By Meagan Parrish • July 15, 2024 -
Stock via Getty Images
Could pharma’s blockbuster immunotherapies work in dogs?
Vetigenics believes it’s found a way to make pricey antibody-based technologies more accessible for animals.
By Alexandra Pecci • July 9, 2024 -
Permission granted by Eli Lilly
FDA approval is just the beginning. Now Lilly’s Kisunla faces the tough Alzheimer’s market.
Recent history suggests an Alzheimer’s approval doesn’t necessarily translate to market triumph. Perhaps for Eli Lilly’s Kisunla, this time could be different.
By Michael Gibney • July 9, 2024 -
Permission granted by GeoVax
In the rapidly shrinking COVID market, this company still sees opportunity
GeoVax is developing a next-gen COVID vaccine targeting a population that’s so far been elusive: immunocompromised patients.
By Alexandra Pecci • July 3, 2024 -
Permission granted by BeiGene
Q&AHow BeiGene is taking on established blockbusters with an expanding blood cancer arsenal
BeiGene’s Brukinsa is the first in a hematology franchise that the company hopes will rival top-sellers and introduce a new lineup of medicines for patients.
By Michael Gibney • July 2, 2024 -
Permission granted by Prologue Medicines
Biotech SpotlightProtein power: a biotech mining viruses to fight disease
Flagship Pioneering-backed Prologue Medicine is harnessing the evolutionary tactics of viral proteins to systematically find new drugs.
By Kelly Bilodeau • July 1, 2024 -
Stock via Getty Images
Up-and-comers look for an edge in the bustling ADC field
The next wave of targeted ADC therapies is on the horizon, and these three potential rising stars could help carry the field forward.
By Meagan Parrish • June 28, 2024
Previous
